Status:
COMPLETED
Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA012JP
Lead Sponsor:
Chugai Pharmaceutical
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
20+ years
Phase:
PHASE3
Brief Summary
This is an open-label, extension, Phase III study to evaluate the long-term safety and efficacy of MRA in patients with RA who participated in Study MRA012JP.
Eligibility Criteria
Inclusion
- Inclusion criteria
- Patients must suffer from RA, and must have participated in the preceding study.
- Patients must have been confirmed to be appropriate on week 52 of the preceding study by X radiography.
- Exclusion criteria
- Patients evaluated as belonging to Steinbrocker's class IV within 4 weeks before administration of the study drug
- Patients who have not been registered by 3 months after week 52 of the preceding study
Exclusion
Key Trial Info
Start Date :
April 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2009
Estimated Enrollment :
241 Patients enrolled
Trial Details
Trial ID
NCT00144547
Start Date
April 1 2004
End Date
June 1 2009
Last Update
August 9 2013
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.